Company intelligence / Profile preview
EPOS-Iasis
Nicosia, Cyprusepos-iasis.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
EPOS-Iasis has pioneered multimodal imaging, nanotheranostics, and cell-based technologies. It has developed prototype systems for preclinical molecular imaging (e.g., mCT-3DOI-FMT), with ongoing translational research bridging molecular imaging and therapeutics for oncology and inflammatory diseases. Key prototypes include molecular probes for EGFR and innovative drug delivery systems for brain tumors.
- Therapeutic areas
- OncologyGastroenterology
- Modalities
- NanoparticleSmall moleculeMolecular probeBiologicTheranostic agent
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
National Medical and Public Health Services (Cyprus)Brain Tumour Patient AssociationAcademic consortia in FP7, H2020, MDCAs, FETOpenIndustrial partners for production and testing (unnamed)
Beyond the preview
Go deeper on EPOS-Iasis.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EPOS-Iasis.